These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 35351998)

  • 21. Targeted proteomics by selected reaction monitoring mass spectrometry: applications to systems biology and biomarker discovery.
    Elschenbroich S; Kislinger T
    Mol Biosyst; 2011 Feb; 7(2):292-303. PubMed ID: 20976349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathway-Informed Discovery and Targeted Proteomic Workflows Using Mass Spectrometry.
    Chu CS; Miller CA; Gieschen A; Fischer SM
    Methods Mol Biol; 2017; 1550():199-221. PubMed ID: 28188532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteomics approaches for myeloid leukemia drug discovery.
    Kapoor I; Pal P; Lochab S; Kanaujiya JK; Trivedi AK
    Expert Opin Drug Discov; 2012 Dec; 7(12):1165-75. PubMed ID: 22971110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Target identification of small molecules based on chemical biology approaches.
    Futamura Y; Muroi M; Osada H
    Mol Biosyst; 2013 May; 9(5):897-914. PubMed ID: 23354001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The evolving role of mass spectrometry in cancer biomarker discovery.
    Wang P; Whiteaker JR; Paulovich AG
    Cancer Biol Ther; 2009 Jun; 8(12):1083-94. PubMed ID: 19502776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Target identification for biologically active small molecules using chemical biology approaches.
    Lee H; Lee JW
    Arch Pharm Res; 2016 Sep; 39(9):1193-201. PubMed ID: 27387321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combining bioinformatics and MS-based proteomics: clinical implications.
    Acosta-Martin AE; Lane L
    Expert Rev Proteomics; 2014 Jun; 11(3):269-84. PubMed ID: 24720436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mass spectrometry-based proteomics in preclinical drug discovery.
    Schirle M; Bantscheff M; Kuster B
    Chem Biol; 2012 Jan; 19(1):72-84. PubMed ID: 22284356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Target deconvolution of bioactive small molecules: the heart of chemical biology and drug discovery.
    Jung HJ; Kwon HJ
    Arch Pharm Res; 2015 Sep; 38(9):1627-41. PubMed ID: 26040984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dipeptidyl peptidase 9 substrates and their discovery: current progress and the application of mass spectrometry-based approaches.
    Wilson CH; Zhang HE; Gorrell MD; Abbott CA
    Biol Chem; 2016 Sep; 397(9):837-56. PubMed ID: 27410463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Target identification of natural and traditional medicines with quantitative chemical proteomics approaches.
    Wang J; Gao L; Lee YM; Kalesh KA; Ong YS; Lim J; Jee JE; Sun H; Lee SS; Hua ZC; Lin Q
    Pharmacol Ther; 2016 Jun; 162():10-22. PubMed ID: 26808165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Solvent-Induced Protein Precipitation for Drug Target Discovery.
    Zhang X; Hu L; Ye M
    Methods Mol Biol; 2023; 2554():35-45. PubMed ID: 36178619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. False-positive rate determination of protein target discovery using a covalent modification- and mass spectrometry-based proteomics platform.
    Strickland EC; Geer MA; Hong J; Fitzgerald MC
    J Am Soc Mass Spectrom; 2014 Jan; 25(1):132-40. PubMed ID: 24114261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deciphering lymphoma pathogenesis via state-of-the-art mass spectrometry-based quantitative proteomics.
    Psatha K; Kollipara L; Voutyraki C; Divanach P; Sickmann A; Rassidakis GZ; Drakos E; Aivaliotis M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Mar; 1047():2-14. PubMed ID: 27979587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Global MS-Based Proteomics Drug Profiling.
    Carvalho AS; Matthiesen R
    Methods Mol Biol; 2016; 1449():469-79. PubMed ID: 27613057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemoproteomic methods for covalent drug discovery.
    Chan WC; Sharifzadeh S; Buhrlage SJ; Marto JA
    Chem Soc Rev; 2021 Aug; 50(15):8361-8381. PubMed ID: 34143170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SEC-TID: A Label-Free Method for Small-Molecule Target Identification.
    Salcius M; Bauer AJ; Hao Q; Li S; Tutter A; Raphael J; Jahnke W; Rondeau JM; Bourgier E; Tallarico J; Michaud GA
    J Biomol Screen; 2014 Jul; 19(6):917-27. PubMed ID: 24554445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enabling parallel protein analysis through mass spectrometry.
    Domon B; Alving K; He T; Ryan TE; Patterson SD
    Curr Opin Mol Ther; 2002 Dec; 4(6):577-86. PubMed ID: 12596360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mass spectrometry approaches to monitor protein-drug interactions.
    Zinn N; Hopf C; Drewes G; Bantscheff M
    Methods; 2012 Aug; 57(4):430-40. PubMed ID: 22687620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemical proteomic strategies for the discovery and development of anticancer drugs.
    Liu Y; Guo M
    Proteomics; 2014 Mar; 14(4-5):399-411. PubMed ID: 24323546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.